ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 77 filers reported holding ORIC PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,607,802 | -63.6% | 2,579,802 | -53.3% | 4.95% | -23.0% |
| Q2 2023 | $42,857,984 | +386.7% | 5,522,936 | +257.5% | 6.42% | +53.8% |
| Q1 2023 | $8,806,500 | +26.7% | 1,545,000 | +30.9% | 4.18% | +10.2% |
| Q4 2022 | $6,950,200 | +132.0% | 1,180,000 | +26.0% | 3.79% | +136.1% |
| Q3 2022 | $2,996,000 | – | 936,334 | – | 1.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |